Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
12.86
-0.27 (-2.06%)
At close: Aug 24, 2026, 4:00 PM EDT
13.24
+0.38 (2.95%)
Pre-market: Aug 25, 2026, 8:24 AM EDT
Candel Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
984.03M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 125.00K | - | - |
| Dec 31, 2021 | 125.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ardelyx | 450.89M |
| Geron | 204.56M |
| Arbutus Biopharma | 181.72M |
| Kura Oncology | 77.23M |
| Wave Life Sciences | 65.37M |
| Lexicon Pharmaceuticals | 41.47M |
| Janux Therapeutics | 24.00M |
CADL News
- 8 days ago - Candel Therapeutics price target raised to $12 from $9 at BofA - TheFly
- 12 days ago - Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 12 days ago - Candel Therapeutics Earnings release: Q2 2026 - Filings
- 12 days ago - Candel Therapeutics Quarterly report: Q2 2026 - Filings
- 12 days ago - Candel Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference - Transcripts
- 21 days ago - Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 22 days ago - Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026 - GlobeNewsWire
- 27 days ago - Candel Therapeutics to Present at Canaccord Genuity's 46th Annual Growth Conference in Boston - GlobeNewsWire